Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.51 |
| ▸ | WDR5 | P61964 | 7/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895980 | 0.84 | ACLY (0.47) | ACLYWDR5MEN1KMT2A | |
| SCHEMBL4889071 | 0.83 | WDR5 (0.52) | ACLYWDR5MEN1KMT2A | |
| SCHEMBL4893777 | 0.81 | SLC22A12 (0.56) | ACLYWDR5MEN1KMT2A | |
| SCHEMBL10702348 | 0.76 | MCL1 (0.70) | MCL1IDH1MEN1KMT2A | |
| SCHEMBL18341159 | 0.75 | P2RX1 (0.67) | ACLYWDR5MCL1IDH1 | |
| SCHEMBL10873130 | 0.74 | SLC22A12 (0.70) | MCL1MEN1KMT2A | |
| SCHEMBL29858793 | 0.73 | WDR5 (0.73) | ACLYWDR5 | |
| SCHEMBL23416215 | 0.71 | MCL1 (0.55) | ACLYMCL1CCKBR | |
| SCHEMBL13615340 | 0.71 | MCL1 (0.60) | ACLYMCL1CCKBRIDH1 | |
| SCHEMBL10871234 | 0.71 | MCL1 (0.53) | MCL1CCKBRIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | claimed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | claimed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | disclosed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | disclosed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | disclosed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255240-A1 | Sulfonamide Derivatives | FABP4, SQOR, CS | ACLY 167/4885WDR5 3228/4885MCL1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.